MarginsXMarginsX
Home › Markets › Health Care › RCKT

Rocket Pharmaceuticals Inc. (RCKT)

RCKT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.16
-6.09% on the day
Market cap
$241.2M
Micro cap
Revenue · 2025
$0
Prior year not contiguous
Net income · 2025
-$223.1M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/0001193125-26-076551-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerRCKT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2015
SEC CIK0001281895

Financials · 2025

LineValue
Revenue$0
Net income-$223.1M
Operating income-$231.7M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$77.6M
Total assets$330.4M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
7.2 months
$95.5M cash at September 30, 2026
Share count, 1 year
+3.2%
2025-10-31 to 2026-11-06 · +23.8% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
-$944K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$95.5M cash; operating cash flow -$39.7M a quarter.Report 2026-09-30
Shares outstanding111,660,283 (2026-11-06); 108,222,228 a year earlier; 90,158,895 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-03-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2026-09-02
AuditorEisnerAmper LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-02-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $34K, sold $979K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$49.2M-$39.1M$95.5M$30.4M$010-Q 2026-11-12
Q2 2026
2026-06-30
$0$123.2M-$39.6M$224.5MNo debt tags$010-Q 2026-08-10
Q1 2026
2026-03-31
$0-$47.6M-$45.4M$49.6MNo debt tags$010-Q 2026-05-07
Q4 2025
2025-12-31
$0-$42.5M-$34.8M$77.6M$0$010-K 2026-02-26
Q3 2025
2025-09-30
$0-$50.3M-$50.4M$75.9MNo debt tags$010-Q 2026-11-12
Q2 2025
2025-06-30
$0-$68.9M-$49.0M$32.8MNo debt tags$010-Q 2026-08-10
Q1 2025
2025-03-31
$0-$61.3M-$55.8M$49.8MNo debt tags$010-Q 2026-05-07
Q4 2024
2024-12-31
$0-$60.3M-$46.9M$163.6MNo debt tags$010-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-3.6%
1 month0.0%
3 months-31.1%
Year to date-34.5%
1 year-27.4%
From 52-week high-56.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CAMPCAMP4 Therapeutics Corporation$3.86+1.58%$242.2M
BIOABioAge Labs Inc.$5.22-5.95%$239.9M
FTHFaeth Therapeutics Inc.$9.28-7.48%$239.8M
ARCTArcturus Therapeutics Holdings Inc.$8.31-0.60%$239.5M
LFCRLifecore Biomedical Inc.$6.42-0.08%$243.2M
QTTBQ32 Bio Inc.$8.29-4.82%$248.1M
AMRNAmarin Corporation plc$11.31-0.62%$233.4M
VNDAVanda Pharmaceuticals Inc.$3.81-4.51%$230.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier